WEST CONSHOHOCKEN, Pa., April 18, 2013 /PRNewswire/ -- AFcell Medical, the leading innovator and designer of surgical birth tissue forms as marketed under its AmnioClear brand, is proud to announce the hiring of David Buche as Chief Operating Officer.
Mr. Buche, who has more than 25 years experience in the biologics and medical device industry, joins AFcell Medical where he will lead new product development, sales force expansion and strategic growth activities.
Most recently Mr. Buche was with Integra Life Sciences as Vice President, Marketing and Product Development, Instruments. Mr. Buche led a team of marketing, research & development, project and regulatory experts who were responsible for driving new products to the market through multiple sales channels for the $180 million division.
Prior to joining Integra, Mr. Buche was Vice President and Chief Operating Officer for a 170 employee division of Synovis Life Technologies. During his 15 year tenure at Synovis, Mr. Buche led consistent growth by driving several new biological products to market, leading the commercialization of a new, regenerative biological technology platform and driving sales growth through exceptional surgical community interaction and sales force expansion.
Prior to Synovis, Mr. Buche held various sales and marketing positions for the Spectranetics Corporation. Spectranetics develops, manufactures and markets laser equipment and single use interventional devices for treating arterial disease.
Mr. Buche served in the US Navy, received executive education from the University of Minnesota, Carlson School of Business and an advanced degree from California Coast University.
Said Robin Young , CEO and Founder of AFcell Medical; "David's extensive experience bringing biologic products to market a
|SOURCE AFcell Medical|
Copyright©2012 PR Newswire.
All rights reserved